Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine.
Several new glutathione adducts (M3-M7) of trazodone were tentatively identified in human liver microsomal incubations using liquid chromatography-tandem mass spectrometry (LC/MS/MS). Following incubations with trazodone in the presence of glutathione, 1-(3'-chlorophenyl)piperazine (m-CPP), a major circulating and pharmacologically active metabolite of several antidepressants including trazodone, nefazodone, and etoperidone, was trapped with glutathione to afford the corresponding quinone imine-sulfydryl adducts M4 and M5. Two novel glutathione adducts of deschloro-m-CPP and deschloro-trazodone, M3 and M6, were also detected by tandem mass spectrometry. The identities of these m-CPP-derived glutathione adducts were further confirmed by LC/MS/MS analyses of microsomal incubations of m-CPP. To investigate the bioactivation mechanism, a regioisomer of m-CPP, 1-(4'-chlorophenyl)piperazine, was incubated in human liver microsomes. Blockage of bioactivation by 4'-chloro-substitution at least partially suggested that formation of m-CPP-derived glutathione adducts M3, M4, and M5 is mediated by a common quinone imine intermediate. A tentative pathway states that upon formation of the trazodone- and m-CPP-1',4'-quinone imine intermediates through initial 4'-hydroxylation, glutathione attacks at the chlorine position by an ipso substitution, resulting in 4'-hydroxy-3'-glutathion-deschloro-trazodone (M6) and 4'-hydroxy-3'-glutathion-deschloro-m-CPP (M3), respectively. In contrast to CYP3A4-dependent bioactivation of trazodone itself, formation of M4 was mediated specifically by CYP2D6, as evidenced by cDNA-expressed CYP2D6-catalyzing formation of M4 from m-CPP, strong inhibition of formation of M4 by quinidine, a specific CYP2D6 inhibitor, in both incubations of trazodone and m-CPP with human liver microsomes, and concentration-dependent inhibition of M4 formation by quinidine.
Wen
Bo
B
Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey, USA. bo.wen@roche.com
Ma
Li
L
Rodrigues
A David
AD
Zhu
Mingshe
M
D018687:Antidepressive Agents, Second-Generation / Q000378:metabolism*; D001711:Biotransformation; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism*; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D008862:Microsomes, Liver / Q000378:metabolism; D010879:Piperazines / Q000378:metabolism*; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000378:metabolism*; D014196:Trazodone / Q000378:metabolism*
D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D011994:Recombinant Proteins; D017366:Serotonin Receptor Agonists; D019389:Cytochrome P-450 CYP2D6; D005978:Glutathione; C015068:1-(3-chlorophenyl)piperazine; D014196:Trazodone